Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a review

Eric O. Haff, Steven M. Dresner, David R. Kelley, Timothy L. Ratliff, Amos Shapiro, William J. Catalona*

*Corresponding author for this work

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

Although many different chemotherapeutic regimens for the treatment of superficial bladder cancer have been used, none are considered ideal. This has stimulated investigations of alternative forms of therapy, including immunotherapy. Contained within this therapeutic category are bacterial agents such as Bacille Calmette-Guerin, Corynebacterium parvum and a streptococcal preparation, OK-432, as well as the interferon inducer polyriboinosinic acid-polyribocytidylic and passive immunotherapy with sensitized pig lymphocytes. With the exception of BCG, most forms of immunotherapy have not been been effective in the treatment of superficial bladder carcinoma. This paper reviews immunotherapy with emphasis on the studies of BCG as prophylaxis against and treatment for superficial transitional cell carcinoma of the bladder.

Original languageEnglish (US)
Pages (from-to)76-85
Number of pages10
JournalWorld journal of urology
Volume3
Issue number2
DOIs
StatePublished - Sep 1 1985

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a review'. Together they form a unique fingerprint.

  • Cite this